AC Immune (NASDAQ:ACIU - Get Free Report)'s share price was down 3.9% on Monday . The stock traded as low as $1.94 and last traded at $1.99. Approximately 150,325 shares changed hands during trading, an increase of 4% from the average daily volume of 145,007 shares. The stock had previously closed at $2.07.
Analyst Ratings Changes
Several analysts have weighed in on ACIU shares. HC Wainwright cut their price objective on AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Wall Street Zen raised AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th.
Check Out Our Latest Analysis on ACIU
AC Immune Stock Up 0.7%
The company's fifty day moving average price is $1.84 and its 200-day moving average price is $2.15. The stock has a market capitalization of $210.36 million, a PE ratio of -3.61 and a beta of 1.62.
AC Immune (NASDAQ:ACIU - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. AC Immune had a negative net margin of 177.79% and a negative return on equity of 44.60%. The firm had revenue of $1.12 million during the quarter, compared to analyst estimates of $1.99 million. Equities research analysts anticipate that AC Immune will post -0.62 earnings per share for the current year.
Hedge Funds Weigh In On AC Immune
A number of hedge funds have recently added to or reduced their stakes in ACIU. Northern Trust Corp purchased a new position in AC Immune in the 4th quarter worth approximately $1,088,000. BVF Inc. IL raised its holdings in AC Immune by 1.5% in the 1st quarter. BVF Inc. IL now owns 19,822,436 shares of the company's stock worth $37,068,000 after acquiring an additional 300,000 shares during the last quarter. Acadian Asset Management LLC raised its holdings in AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company's stock worth $679,000 after acquiring an additional 172,796 shares during the last quarter. Renaissance Technologies LLC raised its holdings in AC Immune by 14.6% in the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company's stock worth $1,999,000 after acquiring an additional 94,191 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in AC Immune by 130.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock worth $355,000 after acquiring an additional 74,358 shares during the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
